Health
Monoclonal Antibody Combo Treatment Reduces Viral Load in COVID – Medscape
Bamlanivimab and etesevimab together were associated with a statistically significant reduction in SARS-CoV-2. Bamlanivimab alone, however, showed no significant…
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.
A combination treatment of neutralizing monoclonal antibodies bamlanivimab and etesevimab was associated with a statistically significant reduction in SARS-CoV-2 at day 11 compared with placebo among nonhospitalized patients who had mild-to-moderate COVID-19, new data indicate.
However, bamlanivimab alone in three different single-infusion doses showed no significant reduction in viral load compared…
Continue Reading
